Roche’s baloxavir marboxil succeeds in phase III flu study
Baloxavir marboxil was discovered by Shionogi & Co. and is being developed globally by the Roche Group (which includes Genentech in the US) and Shionogi & Co. The drug
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Papillon Therapeutics’ PPL-001, aimed at treating Friedreich's ataxia, a rare neurodegenerative disorder.
Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president
The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a